23 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
5 Oct 23
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
7:15am
on these trends and continuing to bring SYFOVRE to people living with this chronic disease.”
Highlights from the launch to date include:
Strong
8-K
EX-99.1
pnl ntkjw
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
424B5
u1sj1sds
9 Jan 20
Prospectus supplement for primary offering
5:25pm
424B5
daqii0f0msfrns0exwe
7 Jan 20
Prospectus supplement for primary offering
4:19pm
8-K
EX-99.1
duyzi 08tgolo
16 Sep 19
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
5:17pm
8-K
EX-99.1
zdi3miegdzs62e7ag
12 Sep 19
Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes
8:34am
8-K
EX-99.1
r7cbo kxok5drdeld8
11 Sep 19
Apellis Pharmaceuticals Announces Proposed Private Offering of
5:13pm
424B5
9r3yd9mzlalhamgdb
7 Mar 19
Prospectus supplement for primary offering
4:28pm
8-K
EX-99.1
qvcla6xz
7 Mar 19
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4:15pm
424B5
zf6i21fr
6 Mar 19
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
patqm0mv525wu30 dm
20 Dec 18
Apellis Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy
7:00am